Press Releases
3M Launches 3M™ Tegaderm™ Matrix Dressing with PHI™ technology
November 17, 2008 11:32 AM Eastern Time
- New technology with naturally occurring cations helps promote balance needed for chronic wound healing -
ST. PAUL, Minn.--(BUSINESS WIRE)--3M Health Care, a worldwide leader in health care products that address wound healing, today announced the launch of 3M™ Tegaderm™ Matrix Dressing with PHI™ technology, the first wound dressing in a platform of products from 3M that uses innovative PHI™ technology. The dressing is indicated for use with chronic, non-infected wounds, including: diabetic ulcers, pressure ulcers (stages II-IV) and venous stasis ulcers and has demonstrated favorable results on hard-to-heal wounds.
“Wound healing can be a long, complex process and can easily become stalled,” said Steve Fletcher, Global Business Manager for Advanced Wound Care, 3M Skin and Wound Care Division. “Because PHI™ technology’s unique formulation helps balance the wound environment, Tegaderm™ Matrix dressing can help advance healing, enabling the wound to progress through the normal healing cascade. This may help save healthcare costs and contribute to better patient outcomes.”
The new dressing from the Tegaderm™ family is comfortable, safe and easy to use. Its unique formulation creates a favorable, moist wound environment that does not harm the patient’s skin, affect tissue integrity or cause maceration. The simple design of the dressing allows the patient to easily apply and remove Tegaderm™ Matrix dressing once out of the wound clinic, helping to increase patient compliance.
What is PHI™ technology?
PHI™ technology consists of a unique blend of cations found naturally in the body, including: potassium, zinc, calcium and rubidium. The technology responds to body temperature and promotes a natural moisture balance to help chronic wounds progress toward healing. PHI™ technology is a novel approach to jump-starting stalled wounds.
In vitro studies showed that the activity of matrix metalloproteinases (MMPs) is decreased with increasing amounts of PHI™ technology surrounding the cells. This is important because in chronic wounds, an imbalance in the production of MMPs and their natural inhibitors (TIMPs) has been shown to slow down the healing process. Along with reduced activity of MMPs in chronic wound fluid, PHI™ technology may aid in rebalancing the wound environment.
For more information on 3M™ Tegaderm™ Matrix Dressing with PHI™ technology, visit our website: http://www.3m.com/tegaderm-matrix.
About 3M Health Care
3M Health Care, one of 3M’s six major business segments, provides world-class innovative products and services to help health care professionals improve the practice, delivery and outcome of patient care in medical, oral care, drug delivery and health information markets. 3M and Tegaderm are trademarks of 3M.
PHI is a trademark of Greystone Pharmaceuticals, Inc. 3M has an exclusive, worldwide licensing agreement to market PHI™ technology in its wound care products.
Schultz G. MP-9 Protease levels as an indicator of wound bed preparation and healing. The World Union of Wound Healing Societies, Third Congress, Toronto, Canada 2008
Soo C, Shaw WW, Zhang X, Longaker MT, Howard EW, Ting K. Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair. Plast Reconstr Surg. 2000 Feb;105(2):638-47
Contacts
3M
Mary Clemens, 651-733-8806
mcclemens@mmm.com
or
WeissComm Partners
Molly Rabinovitz, 312-646-6294
mrabinovitz@wcpglobal.com
Permalink: http://www.businesswire.com/news/3m/20081117006319/en
3M launch Tegaderm Matrix accelerated wound healing dressing, during scientific session with UAE’s medical community
Wed, 18 Feb 2009
3M Health Care division, a leading provider of medical and oral care, drug delivery and health information systems – a part of 3M, the technology company that produces thousands of innovative products for dozens of diverse industries, yesterday held a scientific session in Abu Dhabi’s Hilton Hotel for the launch of a wound dressing innovation designed to offer faster healing in difficult-to-heal wounds: the Tegaderm Matrix Dressing with PHI™.
To an audience of surgeons including specialist surgeons, podiatrists, doctors, nurses, representatives from the UAE’s Ministry of Health and other medical professionals; Cathy Harley, Global Consultant in Wound Care and W. C. Technology discussed the phenomenal breakthrough in wound healing that the Tegaderm Matrix Dressing represents by providing faster healing in chronic wounds, and gave a demonstration on its use to the assembled medical community.
"In some patients with specific medical issues or complications, wounds may take a long time to heal, if at all. As a product designed specifically for accelerated wound healing, 3M Tegaderm Matrix works to normalize the wound environment, regulate MMPs in the wound bed and facilitate re-epithelialization," explained Harley. "The launch of our Tegaderm Matrix Dressing with PHI™ means that patients across the Middle East that suffer from chronic wounds or ulcers will benefit from a product that is truly best in class, and a significant improvement on all existing methods of wound protection currently available and used in the medical world."
3M Health Care remains committed to discovering, designing and producing innovative health care technologies that not only aid medical professionals in their work, but that offer greater protection and safety to patients, to expedite healing and recovery. click here for the full press release
Fort Myers pharmaceutical firm going worldwide
www.FloridaWeekly.com
July 23, 2008
3M Health Care and Fort Myers-based Greystone Pharmaceuticals, Inc. have entered into an exclusive, worldwide license agreement for wound care products using Greystone's patented PHI technology, a proprietary formulation that aids in the management of hard-to-heal wounds.
This is the second agreement between 3M Health Care and Greystone Pharmaceuticals, Inc. The first agreement provided 3M Health Care limited distribution rights in Canada and parts of Europe. This new agreement broadens 3M Health Care's rights to the United States and most major countries in the world.
"This license agreement will enhance 3M Health Care's rapidly growing advanced wound care business and builds on our reputation as a global leader in the treatment of chronic wounds," said Bill Cruise, skin and wound care global business director for 3M Health Care. "Greystone's innovative PHI technology is proving to be effective in managing hard-to-heal wounds, and combining this technology with our extensive global coverage will benefit patients and clinicians worldwide."
"We have developed an innovative wound care technology that can help patients with chronic and non-responding wounds return to more active and productive lives," said Greg Pilant, Greystone's CEO. "With 3M Health Care's global presence and deep expertise in advanced wound care, we believe we can bring valuable solutions to patients globally." click here for the full press release
Greystone Prepares to Expand Factory Space
Company to Increase Output of Wound Care Products in Deal With 3M Co.
July 19, 2008
Greystone Pharmaceuticals plans to more-than-double the size of its Memphis factory to make enough wound-care products to service the massive licensing and distribution deal that it signed this month with the health care arm of Minnesota-based 3M Co. The total size of the building on Florida Street just south of Downtown will increase from 8,000 feet to 22,000 feet over the next year, said Greg P. Pilant, Greystone's chairman and CEO. Click here for full press release.
Greystone Pharmaceuticals, Inc. and 3M Health Care Announce Licence Agreement for Innovative Wound Care Technology
July 17, 2008
3M Health Care and Greystone Pharmaceuticals, Inc. today announce they have entered into an exclusive, worldwide license agreement for wound care products using Greystone’s patented PHI technology, a proprietary formulation that aids in the management of hard-to-heal wounds. Click here for full press release.
Greystone Pharmaceuticals, Inc. Announces Appointment of Chief Medical Director
April 28, 2007
Fort Myers, FL – Dermagenics U.S., Inc., a subsidiary of Greystone Pharmaceuticals Inc., today announces the appointment of I. Kelman Cohen, M.D. as Chief Medical Officer. Click here for full press release.
Greystone Pharmaceuticals, Inc. and 3M Health Care announce supply and distribution agreement
3M to distribute product made by Greystone in the U.K.
April 19, 2007
Fort Myers, Florida – Greystone Pharmaceuticals, Inc. of Fort Myers, Florida, announced today that it has signed an agreement with 3M Health Care Limited of Loughborough, England for the supply and distribution of Greystone’s advanced wound care dressing, DerMax®, in the United Kingdom. Under the agreement, 3M Health Care Limited will brand and distribute DerMax in the U.K. Greystone's European wound care products subsidiary, Dermagenics Europe, BV, will manufacture the product for 3M. Click here for full press release.
New wound care technology debuted at international conference
Ostomy Wound Management
January 26, 2007
Greystone Pharmaceuticals, Inc. (Memphis, Tenn.), through its European subsidiary Dermagenics BV, announced the U.K. launch of its chronic wound technology — Epi-Max EU®.
Epi-Max EU® is noted for use as a wound dressing to manage diabetic ulcers, decubitus ulcers, leg ulcers, and acute severe wounds where fast epithelialization is required. This is the first wound care product permitted to claim the ability to downregulate matrix metalloproteinase production (MMP). Studies demonstrate this downregulation enhances chronic and acute severe wound healing.
The product is currently marketed and sold under the DerMax® name throughout Europe and the Middle East. Encouraged by the success of DerMax® throughout the continent, Dermagenics looks forward to presenting this state-of-the-art technology globally to provide the healthcare community with wound care alternatives that are effective in accelerating the wound healing process.
Epi-Max EU® made its United Kingdom debut at the Wounds U.K. International Conference held in Harrogate on November 13-15, 2006. The product, which has been approved for the Drug Tariff List, is now available for distribution.
Tennessee Medicare Health Support Program offers monitoring technologies, transportation services to participants
April 11, 2006
XLHealth, one of the nation's fastest-growing disease management companies, and Greystone Pharmaceuticals, Inc., an expert in the development of advanced patient monitoring technologies, have joined forces to facilitate access to health support services for participants in Tennessee's new Medicare Health Support program. Through this partnership, participants in the Medicare Health Support program, which is sponsored by the Centers for Medicare & Medicaid Services and operated in Tennessee by XLHealth, will be offered transportation services and state-of-the-art home health testing equipment as necessary. Click here for the full press release.
Greystone Pharmaceuticals, Inc. to expand into Lee County, Florida
March 14, 2006
Greystone Pharmaceuticals, Inc., a biotech development company specializing in medical devices and pharmaceutical products, has announced its decision to open a corporate headquarters for their holding company in Lee County, Florida. Click here for the full press release.